Evidence map›Paper›PMID 41210991›Full record

ArticleiScience2025

Comprehensive molecular analysis of uveal melanoma identifies targets in tumor-intrinsic and tumor-extrinsic pathways.

Linda A Cernichiaro-Espinosa, Gustavo A Miranda-Carboni, David J Taylor-Gonzalez, Sue Choi, Anthony Cruz, Robert Musicante, Braden Cox, Stephanie Allen-Winters, Yinan Wang, Chuan He Yang and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in iScience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Linda A Cernichiaro-EspinosaDepartment of Ophthalmology, Hamilton Eye Institute, The University of Tennessee Health Science Center, 930 Madison Avenue, Ste 200, Memphis, TN 38163, USA.
Gustavo A Miranda-CarboniDepartment of Medicine Division of Hematology and Oncology, Center for Cancer Research, The University of Tennessee Health Science Center, 19 South Manassas St, Memphis, TN 38163, USA.
David J Taylor-GonzalezDepartment of Ophthalmology, Hamilton Eye Institute, The University of Tennessee Health Science Center, 930 Madison Avenue, Ste 200, Memphis, TN 38163, USA.
Sue ChoiCollege of Medicine, The University of Tennessee Health Science Center, 910 Madison Avenue, Ste 1031, Memphis, TN 38163, USA.
Anthony CruzCollege of Medicine, The University of Tennessee Health Science Center, 910 Madison Avenue, Ste 1031, Memphis, TN 38163, USA.
Robert MusicanteCollege of Medicine, The University of Tennessee Health Science Center, 910 Madison Avenue, Ste 1031, Memphis, TN 38163, USA.
Braden CoxCollege of Medicine, The University of Tennessee Health Science Center, 910 Madison Avenue, Ste 1031, Memphis, TN 38163, USA.
Stephanie Allen-WintersDepartment of Pathology and the Center for Cancer Research, The University of Tennessee Health Science Center, 19 South Manassas St, Memphis, TN 38163, USA.
Yinan WangDepartment of Pathology and the Center for Cancer Research, The University of Tennessee Health Science Center, 19 South Manassas St, Memphis, TN 38163, USA.
Chuan He YangDepartment of Pathology and the Center for Cancer Research, The University of Tennessee Health Science Center, 19 South Manassas St, Memphis, TN 38163, USA.
Vanessa Morales-TiradoDepartment of Ophthalmology, Hamilton Eye Institute, The University of Tennessee Health Science Center, 930 Madison Avenue, Ste 200, Memphis, TN 38163, USA.
Lawrence M PfefferDepartment of Pathology and the Center for Cancer Research, The University of Tennessee Health Science Center, 19 South Manassas St, Memphis, TN 38163, USA.
Matthew W WilsonDepartment of Ophthalmology, Hamilton Eye Institute, The University of Tennessee Health Science Center, 930 Madison Avenue, Ste 200, Memphis, TN 38163, USA.

Funding

Therapeutic targeting of the SWI/SNF chromatin remodeler to regulate GBM chemosensitivityR01CA281977 · NCI · UNIVERSITY OF TENNESSEE HEALTH SCI CTR · PI DUANE D MILLER, LAWRENCE MARC PFEFFER · 2023 to 2026
$2.0M
NCI NIH HHS R01 CA281977
6 · The paper itself

Abstract

In uveal melanoma (UM), the most common primary intraocular tumor, up to half of patients develop fatal metastases despite high local tumor control. Effective treatments for genetically high-risk tumors remain limited, largely due to challenges posed by cancer stem cells (CSCs) and the tumor microenvironment (TME), which sustain tumor progression and resistance. Our study evaluated stemness properties in UM tumor cells, focusing on

Indexed as

Biological sciencesCancerOncology

Identifiers

PMID41210991
PMCPMC12594941

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.